| Date | Title | Description |
| 27.10.2025 | Shanton Pharma Completes EOP2 Meeting with US FDA for Refractory Gout Program | SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout
SINGAPORE and PRINCETON, N.J., Oct. 27, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech developing a novel treatme... |
| 25.07.2025 | Shanton Receives Fast Track Designation from US FDA for Refractory Gout Program | SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout
SINGAPORE and PRINCETON, N.J., July 25, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel... |
| 19.05.2025 | Shanton to Present Topline Data from Phase 2b Study with SAP-001 in Refractory Gout Patients at EULAR 2025 Congress | SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout
SINGAPORE and PRINCETON, N.J., May 19, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel ... |
| 28.03.2025 | Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients | SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout
SINGAPORE and PRINCETON, N.J., March 28, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a nove... |
| 05.08.2024 | Shanton Reaches Full Enrollment in Phase 2b Refractory/Tophaceous Gout Study with SAP-001 | SAP-001 is Shanton's lead investigational compound with Best-in-Class potential in uncontrolled gout
PRINCETON, N.J., Aug. 5, 2024 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a groundbreaking treatment for re... |
| 09.01.2023 | Shanton Screens First Subjects in Phase 2b Refractory/Tophaceous Gout Study with SAP-001 | SAP-001 is an oral once-a-day investigational gout product with Best-in-Class potential for acute and chronic use in uncontrolled patients
BRIDGEWATER, N.J., Jan. 9, 2023 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company deve... |
